US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Karyopharm Therapeutics Inc. - Common Stock (NQ:KPTI)

0.5175 -0.0286 (-5.24%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karyopharm Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
From Pomerantz LLP
Via GlobeNewswire
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Posts Q1 Beat and Highlights ASCO Presentation, Shares Surge 7% ↗
Via Chartmill
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q4 Revenue Miss and Wider Loss, Stock Falls in Pre-Market ↗
Via Chartmill
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Karyopharm Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript ↗
Biotech pivots to hematology after endometrial cancer setback, faces debt deadline. 
Via The Motley Fool
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
From Pomerantz LLP
Via GlobeNewswire
News headline image
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is... 
Via Benzinga
Topics Earnings
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
From Pomerantz LLP
Via GlobeNewswire
Top movers in Friday's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts ↗
Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral... 
Via MarketBeat
News headline image
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus ↗
Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO... 
Via MarketBeat
News headline image
Karyopharm (KPTI) Q1 2026 Earnings Transcript ↗
Karyopharm (KPTI) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Karyopharm Therapeutics Q1 Earnings Call Highlights ↗
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in... 
Via MarketBeat
Topics Earnings
News headline image
Karyopharm (KPTI) Q2 2025 Earnings Transcript ↗
Karyopharm (KPTI) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Karyopharm (KPTI) Q1 2025 Earnings Transcript ↗
Karyopharm (KPTI) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Registration Momentum Builds Across the Oncology Pipeline
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript ↗
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Derivatives Earnings
News headline image
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Reports Q3 2025 Revenue Beat and Earnings Miss ↗
Karyopharm (KPTI) Q3 2025 results show a revenue beat but an earnings miss. The stock rose pre-market as investors focus on XPOVIO sales growth and key Phase 3 data due in 2026. 
Via Chartmill
Topics Earnings
News headline image
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026 ↗
Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 million Q3 revenue, and advances Phase 3 selinexor trial. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >